The use of conjugated estrogens and bazedoxifene for the management of vasomotor symptoms in premenopausal and menopausal patients with endometriosis: a systematic review
Systematic review / meta-analysis
OA: closed
CC0
AI-generated summary
This systematic review found limited, high-risk evidence from two case reports/series on conjugated estrogens/bazedoxifene for endometriosis patients, suggesting potential symptom relief but lacking data on efficacy and safety.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: This systematic review investigated the impact of conjugated estrogens/bazedoxifene (CE/BZA) for treating perimenopausal and menopausal symptoms in patients with a history of endometriosis.
METHOD: The review followed PRISMA guidelines and was prospectively registered with PROSPERO (CRD42024617174). Without randomized controlled trials (RCTs), the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports and Case Series assessed methodology and risk of bias. An information specialist completed the search in June 2025 using Ovid MEDLINE, PubMed, Ovid EMBASE, and Web of Science, combining controlled vocabularies and keywords for dysmenorrhea, dyspareunia, endometriosis, perimenopausal, postmenopausal, menopause hormone therapy, Duavive, and CE/BZA. Eligible studies included RCTs, cohort studies, case reports, and case-control studies evaluating CE/BZA for vasomotor symptoms in premenopausal and menopausal endometriosis patients.
RESULTS: Of 1540 retrieved studies, two coauthors (J.C.M.-G., E.S.) independently screened titles and abstracts, selecting 20 for full-text review. Only two publications met inclusion criteria, one case report and one case series, representing nine patients (four detailed, five additional). No RCTs, cohort, or case-control studies directly addressed CE/BZA in endometriosis. Preliminary narrative evidence suggests pain and vasomotor symptom relief, though findings carry high risk of bias.
CONCLUSION: Because bazedoxifene antagonizes estrogen receptors and endometriosis is estrogen-dependent, CE/BZA may alter systemic inflammation or endothelial function. Although preclinical models show reduced lesion size, human evidence remains extremely limited and biased, insufficient to assess lesion recurrence or vascular safety. CE/BZA is currently indicated only for postmenopausal vasomotor symptoms; preliminary anecdotal evidence suggests symptom improvement, but large-scale comparative trials are urgently needed to establish safety and efficacy in endometriosis.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (18)
- Bazedoxifene-Conjugated Estrogens for Treating Endometriosis via openalex
- Bazedoxifene/conjugated estrogens in combination with leuprolide for the treatment of endometriosis via openalex
- Effect of bazedoxifene on expressions of VEGF, VEGFR2, COX-2 and inflammatory factors in a rat endometriosis model via openalex
- Endometriosis: A Comprehensive Exploration of Inflammatory Mechanisms and Fertility Implications via openalex
- Endometriosis and menopause-management strategies based on clinical scenarios via openalex
- Medical Management of Endometriosis via openalex
- Progesterone Resistance in Endometriosis: Current Evidence and Putative Mechanisms via openalex
- Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model via openalex
- Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model via openalex
- W2002573431 via openalex
- W2126676279 via openalex
- W2056529697 via openalex
- W2968947572 via openalex
- W2010770199 via openalex
- W4399505405 via openalex
- W2007872498 via openalex
- W2168495346 via openalex
- W2210737500 via openalex
SciLite annotations
chemicals 5
estrone
bazedoxifene
estrone
bazedoxifene
estrogen
organisms 1
human
Source provenance
- europepmc
- last seen: 2026-10-13T06:10:10.580696+00:00
- openalex
- last seen: 2026-08-03T06:04:05.111620+00:00
- pubmed
- last seen: 2026-10-13T06:04:56.726061+00:00
- scilite
- last seen: 2026-07-19T09:54:07.271699+00:00
- unpaywall
- last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0
· commercial use OK